PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Rischin, D.; Spigel, D.; Adkins, D.; Wein, R.; Arnold, S.; Singhal, N.; Lee, O.; Murugappan, S.

doi:10.1002/hed.24311

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Date

2016

Authors

Rischin, D.

Spigel, D.

Adkins, D.

Wein, R.

Arnold, S.

Singhal, N.

Lee, O.

Murugappan, S.

Type:

Journal article

Citation

Head and Neck, 2016; 38(S1):E1756-E1761

Statement of Responsibility

Danny Rischin, David R. Spigel, Douglas Adkins, Richard Wein, Susanne Arnold, Nimit Singhal, Oliver Lee, Swami Murugappan

DOI

10.1002/hed.24311

Abstract

Abstract not available

Description

Published online 17 December 2015

Rights

Published Version

https://doi.org/10.1002/hed.24311

Persistent link to this record

http://hdl.handle.net/2440/102063

Full item page

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Date

Authors

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Citation

Statement of Responsibility

Conference Name

DOI

Abstract

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

License

Grant ID

Published Version

Call number

Persistent link to this record